Product Candidates Indication Development Stage Status
Development Programs Preclinical Phase 1 Phase 2 Phase 3
VK2809 (TRb Agonist) NASH
60%

Phase 2b VOYAGE trial ongoing
VK0214 (TRb Agonist) X-ALD
35%

Phase 1b
VK2735 (Dual GLP-1/GIP agonist) Metabolic disorders
35%

Phase 1 ongoing
Other Programs Preclinical Phase 1 Phase 2 Phase 3
VK5211 (SARM) Hip fracture, muscle wasting
60%

Phase 2 completed
VK0612 (FBPase inhibitor) Type 2 Diabetes
60%

Phase 2a completed
VK1430 (DGAT-1 inhibitor) Hypertriglyceridemia, NASH
22%

Preclinical

Product/Target Indication Phase
VK2809 (TRb Agonist) NASH Phase 2
VK0214 (TRb Agonist) X_ALD Phase 1
VK5211 (SARM) Hip fracture, muscle wasting Phase 2
VK0612 (FBPase inhibitor) Hip fracture, muscle wasting Phase 2
VK1430 (DGAT-1 inhibitor) Hypertriglyceridemia, NASH Phase 1